Akribion Therapeutics
Last verified 2026-05-16. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $8.6Mattributed |
|---|---|
| Latest round | seed, $8.6M, 2025-02-01attributed |
| Founded | 2022 |
| Headquarters | Zwingenberg, Germany |
| Industry | bio |
| Stage | seed |
| Website | akribion.de |
akribion.de refused the connection at fetch time; per the .com property Akribion develops the G-dase E RNA-guided nuclease for programmable cell depletion in precision oncology. It targets clinicians treating HPV-induced head-and-neck cancers initially. Differentiator: single-nucleotide specificity with rapid gRNA retargeting.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2025-02-01 | seed | $8.6M | undisclosed |
Provenance
| Fact | Status | Basis |
|---|---|---|
| Seed, $8.6M | attributed | sifted named as publisher. No document URL on file. |
| Total raised $8.6M | attributed | sifted named as publisher. No document URL on file. |
| Company existence | self-reported | akribion.de, read 2026-05-16 |
| Description | self-reported | akribion.de, read 2026-05-16 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.